Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07140120 · ClinicalTrials.gov registry record
LiveSMART Trial to Prevent Falls in Patients With Cirrhosis - Supplementary Study
A clinical trial of Cirrhosis, Liver and Portal Hypertension, sponsored by University of Michigan.
- Active
- Registry status
- 52
- Enrollment target
- 3
- Study locations
NCT07140120 is a study of Cirrhosis, Liver and Portal Hypertension that is active but no longer recruiting, run by University of Michigan. The registered enrollment target is 52 participants, below the 241-participant average among 34 other Cirrhosis, Liver trials with a reported enrollment target (78% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT07140120, a study of Cirrhosis, Liver and Portal Hypertension, is active but no longer recruiting, sponsored by University of Michigan.
- ACTIVE NOT RECRUITING
- Registry status
- 52 participants
- Enrollment target
- 3
- Study locations
Study Summary
The LIVE-SMART supplementary study will assess social determinants of health (income, education, neighborhood deprivation), financial burden (out-of-pocket costs, productivity loss), financial distress (patient and caregiver-reported outcomes), and financial toxicity (healthcare utilization) among LIVE-SMART participants and their caregivers. Participants for this supplementary study are participants in the primary study (NCT05794555) and their caregivers.
Conditions Studied
Study Locations (3)
Michigan
- University of Michigan - Ann Arbor
Pennsylvania
- University of Pennsylvania - Philadelphia
Texas
- Baylor Scott & White Research Institute (BSW) - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2023-06-13 |
| Est. Completion | 2026-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07140120
The ClinicalTrials.gov registry entry for NCT07140120 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 241-participant average among 34 other Cirrhosis, Liver trials with a reported enrollment target (78% lower). The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cirrhosis, Liver appearing as the primary indexed condition, and to 0 interventions.
NCT07140120 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Michigan, Pennsylvania, Texas.
Frequently Asked Questions
What is clinical trial NCT07140120 about?
NCT07140120 is a clinical study titled "LiveSMART Trial to Prevent Falls in Patients With Cirrhosis - Supplementary Study". The LIVE-SMART supplementary study will assess social determinants of health (income, education, neighborhood deprivation), financial burden (out-of-pocket costs, productivity loss), financial distress (patient and caregiver-reported outcomes), and financial toxicity (healthcare utilization) among L...
What is the current status of trial NCT07140120?
This trial is currently active not recruiting. The enrollment target is 52 participants. The study started on 2023-06-13. Estimated completion is 2026-06.
What conditions does trial NCT07140120 study?
This clinical trial studies the following conditions: Cirrhosis, Liver, Portal Hypertension.
Who is sponsoring clinical trial NCT07140120?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07140120 being conducted?
This trial has 3 study locations across Michigan, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cirrhosis, Liver
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics
RECRUITING · Phase 1
-
Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
RECRUITING · Phase 4
-
Measuring Patient Reported Needs in Outpatient Liver Disease Management
RECRUITING
-
Molecular Mechanism of Exercise in Cirrhosis
RECRUITING · NA
-
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
RECRUITING · Phase 2
-
Development of 4D Flow MRI for Risk Stratification of Variceal Bleeding in Cirrhosis
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.